PTJ
RXRX icon

Paul Tudor Jones’s Recursion Pharmaceuticals RXRX Stock Holding History

Paul Tudor Jones’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-265,296
Closed -$883K – 4184
2026
Q1 		$814K Buy
+265,296
New +$1.03M ﹤0.01% 2505
2023
Q4 		– Sell
-21,544
Closed -$165K – 2828
2023
Q3 		$165K Buy
+21,544
New +$215K ﹤0.01% 2113
2022
Q2 		– Sell
-11,914
Closed -$85K – 2469
2022
Q1 		$85K Buy
+11,914
New +$127K ﹤0.01% 1845

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Paul Tudor Jones's RXRX Position: Q2 2026 in Review

Paul Tudor Jones sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 265,296 shares — an estimated $883K sold.

Paul Tudor Jones first reported a position in RXRX in Q1 2022 and held it in 3 quarters. The position peaked at $814K in Q1 2026. 339 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Paul Tudor Jones reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 265,296 Recursion Pharmaceuticals shares in Q2 2026, an estimated $883K.
  • Paul Tudor Jones first reported a position in Recursion Pharmaceuticals in Q1 2022 and held it in 3 quarters.
  • Paul Tudor Jones's Recursion Pharmaceuticals position peaked at $814K in Q1 2026.
  • 339 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.